Fluconazole
Fluconazole is active against most Candida species other than C. krusei, which is intrinsically resistant, and many strains of C. glabrata, which are increasingly resistant. Fluconazole has good activity against Cryptococcus spp. but no clinically important activity against most molds, containing Aspergillus spp., Fusarium spp. and Zygomycetes.
Fluconazole, which is available in both oral (tablets and suspension) and intravenous preparations, is approved by the FDA for treatment of cryptococcal meningitis, vaginal, oropharyngeal and esophageal candidiasis, and for prophylaxis against candidiasis in patients undergoing bone marrow transplantation.